What is ResBiotic?
Founded in 2020 and headquartered in Birmingham, Alabama, ResBiotic operates at the intersection of biotechnology and respiratory health. The company specializes in the development of proprietary microbiome-based products designed to address chronic and acute respiratory conditions. By leveraging the complex interactions within the human microbiome, ResBiotic aims to provide novel therapeutic solutions that move beyond traditional symptom management. Its market position is defined by a commitment to rigorous scientific validation and a focus on the burgeoning field of gut-lung axis research, which is increasingly recognized as a critical frontier in modern medicine.
How much funding has ResBiotic raised?
ResBiotic has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2021): $3M with participation from Timberline Holdings
Key Investors in ResBiotic
Timberline Holdings
Timberline Holdings is a Birmingham-based family investment firm that focuses on growth through intelligent and innovative investing while minimizing reputational risk.
What's next for ResBiotic?
Following this major strategic investment, ResBiotic is expected to scale its clinical trial infrastructure and expand its product pipeline. The current funding context suggests the company is transitioning from early-stage research into a more robust commercialization phase. Future milestones will likely involve securing regulatory approvals and establishing strategic partnerships with larger pharmaceutical entities to facilitate broader market access. As the firm continues to refine its microbiome-based platform, it remains a key player to watch within the Alabama biotechnology ecosystem, particularly as it seeks to translate laboratory breakthroughs into scalable, patient-centric respiratory health solutions.
See full ResBiotic company page
